Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
  • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
  • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/56—Nitrogen atoms
  • C07D211/58—Nitrogen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D211/74—Oxygen atoms
  • C07D211/76—Oxygen atoms attached in position 2 or 6

Definitions

• the present invention relates to new substituted arylaliphatic compounds, a process for their preparation and the pharmaceutical compositions containing them as active principle.
• the present invention relates to a new class of substituted arylaliphatic compounds for therapeutic use, in pathological phenomena which involve the tachykinin system such as for example in a nonlimiting and exclusive manner: pain (D. Regoli et al., Life Sciences , 1987,
• Tachykinins are distributed in both the central nervous system and the peripheral nervous system. Tachykinin receptors have been recognized and are classified into three types: NK 1 , NK 2 , NK 3 .
• Substance P is the endogenous ligand for NK 1 receptors, neurokinin A (NK A ) for NK 2 receptors and neurokinin B (NK B ) for NK 3 receptors.
• NK 1 , NK 2 , NK 3 receptors have been demonstrated in different species.
• CP-96345 J. Med. Chem., 1992, 35, 2591-2600
• RP-68651 Proc. Natl. Acad. Sci. USA , 1991, 88, 10208-10212
• SR 140333 Rel. J.
• SR 48968 For the NK 2 receptor, a selective non-peptide antagonist, SR 48968 has been described in detail (Life Sciences., 1992, 50, PL101-PL106).
• NK 3 receptor certain non-peptide compounds have been described as having an affinity for the NK 3 receptor of the rat and guinea pig brain.
• Patent application EP-A-336230 describes peptide derivative antagonists of substance P and of neurokinin A useful for the treatment and prevention of asthma.
• EP-A-0630887 and international WO 94/10146, WO 94/29309, WO 94/26735 describe antagonists of the neurokinin receptors, all characterized by the structure of formula:
• W represents a direct bond or a methylene
• substituted arylaliphatic compounds having the structure of formula (A) above in which W represents an oxygen atom, or an optionally substituted nitrogen atom, have a very high affinity for receptors for neurokinins.
• the subject of the present invention is the compounds of formula:
• - W 1 represents an oxygen atom; a group -NR- in which R represents a hydrogen, a (C 1 -C 7 ) alkyl or a benzyl;
• R 1 represents hydrogen or a (C 1 -C 4 ) alkyl group
• - R 2 represents a hydrogen; a (C 1 -C 7 ) alkyl; ⁇ - (C 1 -C 4 ) alkoxy- (C 2 - C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene; ⁇ -hydroxy- (C 2 -C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkylthio- (C 2 -C 4 ) alkylene; a ⁇ - (C 1 - C 4 ) alkoxycarbonyl- (C 2 -C 4 ) alkylene; ⁇ -carboxy- (C 2 -C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkylcarbonyl- (C 2 -C 4 ) alkylene; a ⁇ -
• n 1, 2 or 3;
• R 4 is hydrogen or a (C 1 -C 4 ) alkyl group, provided that T represents -CH 2 - when Q is oxygen and one of the groups
• - Z represents an optionally substituted mono-, di- or tricyclic aromatic or heteroaromatic group
• - Ar represents a phenyl which is unsubstituted or substituted one or more times by a substituent chosen from: a halogen atom, a hydroxy, a (C 1 -C 4 ) alkoxy, a (C 1 -C 4 ) alkyl, a trifluoromethyl , a methylenedioxy, said substituents being identical or different; a thienyl unsubstituted or substituted by a halogen atom; a benzothienyl unsubstituted or substituted by a halogen atom; naphthyl unsubstituted or substituted by a halogen atom; an indolyl which is unsubstituted or N-substituted by a (C 1 -C 4 ) alkyl or a benzyl; imidazolyl unsubstituted or substituted by a halogen atom; a pyridyl which is
• R 5 represents a (C 1 -C 7 ) alkyl or a phenyl
• - R 6 and R 7 each independently represent a hydrogen or a (C 1 - C 7 ) alkyl
• R 7 can also represent a (C 3 -C 7 ) cycloalkyl, a (C 3 - C 7 ) cycloalkylmethyl, a phenyl or a benzyl; or else R 6 and R 7 together with the nitrogen atom to which they are linked constitute a heterocycle chosen from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, perhydroazepine or piperazine unsubstituted or substituted for position 4 with a (C 1 -C 4 ) alkyl;
• R 8 and R 9 each independently represent a hydrogen or a (C 1 - C 7 ) alkyl; R 9 may also represent a (C 3 -C 7 ) cycloalkylmethyl or a benzyl;
• R 10 represents a hydrogen; a (C 1 -C 7 ) alkyl; vinyl; phenyl; benzyl; pyridyl; a (C 3 -C 7 ) cycloalkyl which is unsubstituted or substituted by one or more methyls;
• R 11 represents a hydrogen or a (C 1 -C 7 ) alkyl
• R 12 represents a (C 1 -C 7 ) alkyl or a phenyl
• R 13 represents a (C 1 -C 7 ) alkyl; an amino free or substituted with one or two (C 1 -C 7 ) alkyls; a phenyl which is unsubstituted or substituted one or more times with a substituent chosen from: a halogen atom, a (C 1 -C 7 ) alkyl, a trifluoromethyl, a hydroxy, a (C 1 -C 7 ) alkoxy, a carboxy , a (C 1 - C 7 ) alkoxycarbonyl, a (C 1 -C 7 ) alkylcarbonyloxy, a cyano, a nitro, an amino free or substituted by one or two (C 1 -C 7 ) alkyls, said substituents being identical or different ;
• R 3 represents a hydrogen; a (C 1 -C 4 ) alkyl; phenyl; benzyl;
• J 1 represents: - ii 1 - either a group
• - Ar represents a phenyl which is unsubstituted or substituted one or more times by a substituent chosen from: a halogen atom, a nitro, a hydroxy, a trifluoromethyl, a (C 1 -C 4 ) alkyl, a (C 1 - C 4 ) alkoxy, methylenedioxy, said substituents being the same or different; pyridyl; thienyl; pyrimidyl; imidazolyl unsubstituted or substituted by a (C 1 -C 4 ) alkyl;
• - Y represents a hydrogen; a (C 1 -C 7 ) alkyl; formyl; a (C 1 - C 7 ) alkylcarbonyl; a cyano; a group - (CH 2 ) q-OH; a (C 1 -C 7 ) alkyl-O- (CH 2 ) q - group; a group - (CH 2 ) q -NR 4 COR 14 ; a group R 15 COO- (CH 2 ) q -; a (C 1 -C 7 ) alkyl-NHCOO- (CH 2 ) q - group; a group -NR 16 R 17 ; a group -CH 2 -NR 18 R 19 ; a group -CH 2 -CH 2 -NR 18 R 19 ; a group - (CH 2 ) q - NR 4 COOR 20 ; a group - (CH 2 ) q -NR 4 SO 2 R 21
• R 4 represents a hydrogen or a (C 1 -C 4 ) alkyl
• R 14 represents a hydrogen; a (C 1 -C 7 ) alkyl; phenyl; pyridyl; vinyl; benzyl; a (C 3 -C 7 ) cycloalkyl which is unsubstituted or substituted by one or more methyls;
• R 4 and R 14 together represents a group - (CH 2 ) u - in which u is equal to three or four;
• R 15 represents a hydrogen; a (C 1 -C 7 ) alkyl; a (C 3 -C 7 ) cycloalkyl which is unsubstituted or substituted by one or more methyls; phenyl; pyridyl;
• R 16 and R 17 each independently represent a hydrogen or a (C 1 - C 7 ) alkyl;
• R 1 7 may also represent a (C 3 -C 7 ) cycloalkylmethyl, a benzyl or a phenyl; or
• R 16 and R 17 together with the nitrogen atom to which they are linked constitute a heterocycle chosen from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, perhydroazepine or piperazine unsubstituted or substituted in position 4 with a (C 1 -C 4 ) alkyl;
• - R 18 and R 19 each independently represent a hydrogen or a (C 1 - C 7 ) alkyl;
• R 19 may also represent a (C 3 -C 7 ) cycloalkylmethyl or a benzyl;
• R 20 represents a (C 1 -C 7 ) alkyl or a phenyl
• R 21 represents a (C 1 -C 7 ) alkyl; a free or substituted amino with one or two
• (C 1 -C 7 ) alkyls a phenyl which is unsubstituted or substituted one or more times with a substituent chosen from a halogen atom, a (C 1 -C 7 ) alkyl, a trifluoromethyl, a hydroxy, a (C 1 -C 7 ) alkoxy, a carboxy, a (C 1 -C 7 ) alkoxycarbonyl, a (C 1 -C 7 ) alkylcarbonyloxy, a cyano, a nitro, an amino free or substituted by one or two (C 1 -C 7 ) alkyls, said substituents being identical or different ;
• R 22 and R 23 each independently represent a hydrogen or a (C 1 - C 7 ) alkyl;
• R 23 may also represent a (C 3 -C 7 ) cycloalkyl, a (C 3 - C 7 ) cycloalkylmethyl, a hydroxy, a (C 1 -C 4 ) alkoxy, a benzyl or a phenyl;
• R 22 and R 23 together with the nitrogen atom to which they are linked constitute a heterocycle chosen from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, perhydroazepine or piperazine unsubstituted or substituted in position 4 with a (C 1 -C 4 ) alkyl;
• - W 2 represents an oxygen atom; a sulfur atom; sulfinyl; a sulfonyl; a group -NR 24 -;
• R 24 represents a hydrogen; a (C 1 -C 4 ) alkyl; a (C 1 -C 4 ) alkylcarbonyl; a group - (CH 2 ) v -NR 25 R 26 ;
• - v is equal to one, two or three;
• R 25 and R 26 each independently represent a hydrogen or a (C 1 -C 4 ) alkyl; or R 25 and R 26 together with the nitrogen atom to which they are linked constitute a heterocycle chosen from pyrrolidine, piperidine or morpholine;
• R 27 represents a (C 1 -C 4 ) alkyl
• - W 3 represents an oxygen atom; a sulfur atom; a group NR 30 in which R 30 represents a hydrogen or a (C 1 -C 3 ) alkyl;
• R 28 represents a hydrogen; a (C 1 -C 6 ) alkyl; a (C 3 -C 6 ) alkenyl in which a vinyl carbon atom is not linked to the nitrogen atom; a
• R 29 represents a hydrogen; a (C 1 -C 6 ) alkyl unsubstituted or substituted by hydroxy and / or by one, two or three fluorine atoms; a (C 3 -C 6 ) cycloalkyl; a (C 1 -C 5 ) alkoxy (only when W 3 represents an oxygen atom); a (C 3 - C 6 ) cycloalkyloxy (only when W 3 represents an oxygen atom); a group -NR 31 R 32 containing from zero to seven carbon atoms; R 29 being other than an (C 1 -C 4 ) unsubstituted alkyl when both W 3 represents an oxygen atom and R 28 represents a phenyl unsubstituted one or more times by a substituent chosen from: an atom d halogen, nitro, hydroxy, trifluoromethyl, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, said substituent
• R 28 and R 29 together constitute a divalent hydrocarbon group L in which position 1 is linked to the carbon atom carrying the substituent W 3 , the divalent hydrocarbon group L being chosen from: a trimethylene, a cis-propenylene , tetramethylene, cis-butenylene, cis-but-3-enylene, cis, cisbutadienylene, pentamethylene or cis-pentenylene, said divalent hydrocarbon group L being unsubstituted or substituted by one or two methyls; - R 31 and R 32 each independently represent a hydrogen, a (C 1 - C 5 ) alkyl or a (C 3 -C 6 ) cycloalkyl; or else R 31 and R 32 together with the nitrogen atom to which they are bonded constitute a heterocycle chosen from: pyrrolidine, piperidine, morpholine, thiomorpholine (or its S-oxide) or unsubstituted
• - W 4 represents a (C 1 -C 8 ) alkyl or a (C 3 -C 8 ) cycloalkyl, said alkyl and cycloalkyl groups being unsubstituted or substituted by one or more substituents chosen from: a halogen atom; a (C 3 -C 6 ) cycloalkyl; a cyano; a nitro; hydroxy; a (C 1 -C 4 ) alkoxy; formyloxy; a (C 1 - C 4 ) alkylcarbonyloxy; arylcarbonyl; heteroarylcarbonyl; an oxo; an imino unsubstituted or substituted on the nitrogen atom with a (C 1 -C 6 ) alkyl, a (C 3 -C 6 ) cycloalkyl, a formyl, a (C 1 -C 4 ) alkylcarbonyl or an arylcarbonyl;
• R 33 and R 34 each independently represent a hydrogen, a (C 1 - C 5 ) alkyl or a (C 3 -C 6 ) cycloalkyl; or else R 33 and R 34 together with the nitrogen atom to which they are linked constitute a heterocycle chosen from: pyrrolidine, piperidine, morpholine, thiomorpholine (or its S-oxide) or unsubstituted or substituted piperazine in position 4 with C 1 -C 4 alkyl;
• R 35 represents a hydrogen or a (C 1 -C 4 ) alkyl
• - W 5 represents an oxygen atom; a sulfur atom; a group -NR 37 ; a group -CHR 42 ;
• R 37 represents a hydrogen or a (C 1 -C 4 ) alkyl; or R 37 together with R 39 constitute an ethylene group or a trimethylene group;
• R 38 and R 39 each independently represent a hydrogen, a (C 1 - C 5 ) alkyl or a (C 3 -C 6 ) cycloalkyl; or R 38 and R 39 together with the nitrogen atom to which they are bonded constitute a heterocycle chosen from: pyrrolidine, piperidine, morpholine, thiomorpholine (or its S-oxide) or unsubstituted or substituted piperazine in position 4 with a (C 1 - C 4 ) alkyl; or alternatively R 38 represents a hydrogen or a (C 1 -C 4 ) alkyl and R 39 together with R 37 constitute an ethylene group or a trimethylene group;
• R 40 and R 41 each independently represent a (C 1 -C 3 ) alkyl
• R 42 represents a cyano; a nitro; an SO 2 R 43 group .
• R 43 represents a (C 1 -C 4 ) alkyl or a phenyl
• W 4 represents a cyclic group or when a substituent of W 4 is a cyclic group or contains a cyclic group, said cyclic groups can also be substituted on a carbon atom by one or more (C 1 -C 3 ) alkyls ; and when a substituent of W 4 contains an aryl group or a heteroaryl group, said aryl or heteroaryl groups can also be substituted one or more times by a substituent chosen from: a halogen atom, a (C 1 -C 4 ) alkyl, a (C 1 -C 4 ) alkoxy, a cyano, a trifluoromethyl , a nitro, said substituents being identical or different;
• W 6 and W 7 each represent hydrogen; or W 6 represents hydrogen and W 7 represents hydroxy;
• W 7 represents a hydrogen and Wg and Wg together with a diradical W 9 and the carbon atom of the piperidine to which they are linked constitute a spirannic cycle in which Wg represents a phenyl which is substituted in ortho position by a diradical W 9 itself linked to Wg, said phenyl being unsubstituted or substituted by a substituent chosen from: a halogen atom, a (C 1 -C 3 ) alkyl, a (C 1 -C 3 ) alkoxy, a hydroxy , a (C 1 -C 3 ) akylthio, a (C 1 -C 3 ) alkylsulfinyl, a (C 1 -C 3 ) alkylsulfonyl; the diradical W 9 represents a methylene, a carbonyl or a sulfonyl; and W 6 represents an oxygen atom or a group -NR 48 - in
• R 33 , R 34 , R 35 , R 36 , R 37 , R 38 and R 39 are as defined above for group B 5 ;
• R 44 represents a hydrogen; a (C 1 -C 5 ) alkyl; aryl; heteroaryl; arylmethyl; heteroarylmethyl;
• R 45 and R4g each independently represent a hydrogen, a (C 1 - C 5 ) alkyl or a (C3-Cg) cycloalkyl; or else R 45 and R 4 g together with the nitrogen atom to which they are linked constitute a heterocycle chosen from: pyrrolidine, piperidine, morpholine, thiomorpholine (or its S-oxide) or piperazine unsubstituted or substituted in position 4 with a (C; [- C4) alkyl;
• -s is zero, one or two;
• R 47 represents a (C 1 -C 6 ) alkyl; a (C 3 -C 6 ) cycloalkyl; aryl; heteroaryl;
• W 8 or a substituent of W 8 contains a cyclic group
• said cyclic group may further be substituted by one or more methyls
• a heteroaryl group, constitutive of Wg or of a substituent of Wg contains a nitrogen atom as a heteroatom
• said nitrogen atom may also be substituted by a (C 1 -C 5 ) alkyl
• Wg or a substituent of Wg contains a (C 1 -C 5 ) alkyl, (C 1 -C 5 ) alkoxy, formyl or (C 1 -C 4 ) alkylcarbonyl group, said (C 1 -C 5 ) alkyl groups ,
• (C 1 -C 5 ) alkoxy, formyl or (C 1 -C 4 ) alkylcarbonyl may also be substituted by a hydroxy, a (C 1 -C 3 ) alkoxy or by one or more halogen atoms, on the condition that a carbon atom linked to a nitrogen atom or to an oxygen atom is not substituted by a hydroxyl or an alkoxy group and on the condition that a carbon atom in ⁇ of a group (C 1 -C 4 ) alkylcarbonyl is not substituted by a chlorine, bromine or iodine atom;
• J 4 represents: vii 1 - either a group
• - W 10 represents a phenyl which is unsubstituted or substituted one to three times with a substituent chosen from: a halogen atom, a (C 1 -C 6 ) alkoxy, a (C 1 - C 6 ) alkyl, a trifluoromethyl, the said substituents being the same or different; a benzyl unsubstituted or substituted one to three times with a substituent chosen from: a halogen atom, a (C 1 -C 6 ) alkoxy, a (C 1 -C 6 ) alkyl, a trifluoromethyl, said substituents being identical or different ; naphthyl unsubstituted or substituted one to three times by a substituent chosen from: a halogen atom, a (C 1 -C 6 ) alkoxy, a (C 1 -C 6 ) alkyl, a trifluoromethyl, said substituents
• - W 11 represents a group -CONHR 49 ;
• R 50 represents a hydrogen, a (C 1 -C 6 ) alkyl or a benzyl
• R 51 represents from one to three substituents chosen from: a hydrogen, a halogen atom, a trifluoromethyl, a (C 1 -C 6 ) alkyl, a (C 1 -C 6 ) alkoxy, said substituents being identical or different ;
• - f and g are each independently zero, one, two, three four or five, provided that f + g is equal to one, two, three, four or five;
• - W 12 represents a direct bond; a (C 1 -C 3 ) alkylene unsubstituted or substituted by an oxo, an OR 52 group, a halogen, a trifluoromethyl, a phenyl itself unsubstituted or substituted one, two or three times by a substituent chosen independently from: hydroxy, cyano, halogen or trifluoromethyl; a group -S (O) k -; a (C 1 -C 3 ) alkylene-S (O) k - group; a group -S (O) k - (C 1 -C 2 ) alkylene; a group -S (O) k -NH-; a group -S (O) j - NR 52 -; a group -S (O) j -NR 52 - (C 1 -C 2 ) alkylene; a group -CONR 52 -; a -CONR
• W 13 represents a group -NR 53 -; an oxygen atom; a sulfur atom; sulfinyl; a sulfonyl; provided that when W 12 represents a direct bond and when W 14 represents a (C 1 -C 3 ) alkylene, W 13 is a group
• - W14 represents a direct bond; a (C 1 -C 3 ) alkylene unsubstituted or substituted by an oxo, an OR 52 group, a halogen, a trifluoromethyl, a phenyl itself unsubstituted or substituted one, two or three times by a substituent chosen independently from: an OR 52 group, a halogen or a trifluoromethyl; a group -S (O) k -; a (C 1 -C 3 ) alkylene-S (O) k - group; a group -S (O) k - (C 1 -C 2 ) alkylene; a group -NHS (O) j -; a group -NH- (C 1 - C 2 ) alkylene-S (O) j -; a group -S (O) j NR 52 -; a group -S (O) j -NR 52 -;
• said cyclic radical being a phenyl, a naphthyl or a heteroaryl group chosen from: a benzimidazolyl, a benzofuranyl, a benzoxazolyl, a furanyl, an imidazolyl, an indolyl, an isoxazolyl, an isothiazolyl, an oxadiazolyl, an oxazolyl, a pyrazinyl pyrazolyl, pyridyl, pyrimidyl, pyrrolyl, quinolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl; and said phenyl, naphthyl or heteroaryl cyclic radical being unsubstituted or substituted one, two or three times with R 54 ;
• R 52 represents a hydrogen; a (C 1 -C 6 ) alkyl which is unsubstituted or substituted once or twice by a substituent independently selected from: hydroxy, oxo, cyano, halogen atom, trifluoromethyl, phenyl itself unsubstituted or substituted by hydroxy, (C 1 -C 3 ) alkyl, cyano, halogen, trifluoromethyl or (C 1 -C 4 ) alkoxy; phenyl, pyridyl or thiophene, said phenyl, pyridyl or thiophene being unsubstituted or substituted one, two or three times with a substituent independently selected from: hydroxy, (C 1 - C 4 ) alkyl, cyano, halogen atom, trifluoromethyl; a (C 1 - C 3 ) alkyloxy;
• R 53 represents a hydrogen; a (C 1 -C 8 ) alkyl unsubstituted or substituted one or more times by a substituent chosen from: a group -OR 52 , an oxo, a group -NHCOR 52 , a group -NR 55 R 56 , a cyano, a halogen atom, trifluoromethyl or phenyl itself unsubstituted or substituted by hydroxy, cyano, halogen atom or trifluoromethyl; a group -S (O) R 57 ; a group -CO 2 R 57 -; a group -SO 2 R 57 ; a -COR 57 group; a group -CONR 56 R 57 ;
• - R 54 represents a hydrogen; a (C 1 -C 6 ) alkyl unsubstituted or substituted once or twice by hydrogen or hydroxy; an oxo; a group -OR 52 ; a halogen atom; trifluoromethyl; a nitro; a cyano; a group -NR 55 R 56 ; a group -NR 55 COR 56 ; a group -NR 55 CO 2 R 56 ; a group -NHS (O) j R 52 ; a group -NR 55 S (O) j R 56 ; a group -CONR 55 R 56 ; a group
• -COR 52 a group -CO 2 R 52 ; a group -S (O) j R 52 ; a heteroaryl group, said heteroaryl being chosen from: a benzimidazolyl, a benzofuranyl, a benzoxazolyl, a furanyl, an imidazolyl, an indolyl, an isoxazolyl, an isothiazolyl, an oxadiazolyl, an oxazolyl, a pyrazinyl, a pyrazolyl, a pyridyl, a pyridyl , quinolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and said heteroaryl being unsubstituted or substituted once or twice with R 58 ;
• R 55 represents R 52 ;
• R 56 represents R 52 ;
• R 55 and R 56 together with the atoms to which they are linked constitute a heterocycle, monocyclic, saturated, of five, six or seven links and containing one or two heteroatoms, said heteroatoms being independently chosen from a nitrogen atom, an oxygen atom or a sulfur atom; said heterocycle being unsubstituted or substituted once or twice by a substituent independently chosen from: hydroxy, oxo, cyano, halogen atom or trifluoromethyl;
• - R 57 represents a (C 1 -C 6 ) alkyl unsubstituted or substituted one, two or three times by a substituent chosen from: a hydroxy, an oxo, a cyano, a group -OR 52 , a group -NR 55 R 56 , a group -NR 55 COR 56 , a halogen atom, a trifluoromethyl or a phenyl itself unsubstituted or substituted once, twice or three times with a substituent independently chosen from hydroxy, oxo, cyano, -NHR 52 group, -NR 55 R 56 group, -NR 55 COR 56 group , halogen atom, trifluoromethyl or (C 1 -C 3 ) alkyl;
• - R 58 represents a hydrogen; a (C 1 -C 6 ) alkyl unsubstituted or substituted once or twice by hydrogen or hydroxy; an oxo; a group -OR 52 ; trifluoromethyl; a nitro; a cyano; a group -NR 55 R 56 ; a group
• the compounds of formula (I) according to the invention include both optically pure isomers and racemates.
• the radical Z may be a phenyl group, which may be unsubstituted or optionally contain one or more substituents.
• Z is a phenyl group, this can be mono substituted or disubstituted in particular in position 2,4 but also for example in position 2,3 or 4,5 or 3,4 or
• 3.5 it can also be trisubstituted, in particular in position 2,4,6 but also for example in 2,3,4 or 2,3,5 or 2,4,5 or 3,4,5; tetrasubstituted, for example in 2,3,4,5; or pentasubstituted.
• the radical Z can also represent a bicyclic aromatic group such as 1- or 2-naphthyl; 1-, 2-, 3-, 4-, 5-, 6-, 7-indenyl, one or more bonds of which may be hydrogenated, said groups possibly being unsubstituted or optionally containing one or more substituents such as: the alkyl group , phenyl, cyano, hydroxyalkyl, hydroxy, oxo, alkylcarbonylamino and alkoxycarbonyl, thioalkyl, halogen, alkoxy, trifluoromethyl, in which the alkyls and alkoxy are C 1 -C 4 .
• a bicyclic aromatic group such as 1- or 2-naphthyl; 1-, 2-, 3-, 4-, 5-, 6-, 7-indenyl, one or more bonds of which may be hydrogenated, said groups possibly being unsubstituted or optionally containing one or more substituents such as: the alkyl group , phenyl
• the radical Z can also be a pyridyl, thiadiazolyl, indolyl, indazolyl, imidazolyl, benzimidazolyl, benzotriazolyl, benzofurannyl, benzothienyl, benzothiazolyl, benzisothiazolyl, quinolyl, isoquinolyl, benzoxazolyl, benzoxoxylyl, benzoxoxylyl, benzoxoxyl) furyle, pyrannyle, ehromenyle, isobenzofurannyle, pyrrolyle, pyrazolyle, pyrazinyle, pyrimidinyle, pyridazinyle, indolizinyle, phtalazinyle, quinazolinyle, acridinyle, isothiazolyle, isochromannyle, chromannyle, carboxyaryl, of which one or more non-substituted groups can be non-sub
• a phenyl which is unsubstituted or substituted one or more times with a substituent chosen from: a halogen atom; trifluoromethyl; a cyano; hydroxy; a nitro; an amino unsubstituted or substituted once or twice by a (C 1 - C 4 ) alkyl; a benzylamino; carboxy; a (C 1 -C 10 ) alkyl; a (C 3 - C 8 ) cycloalkyl which is unsubstituted or substituted one or more times with methyl; a (C 1 -C 10 ) alkoxy; a (C 3 -C 8 ) cycloalkyloxy unsubstituted or substituted one or more times with methyl; a mercapto; a (C 1 -C 10 ) alkylthio; formyloxy; a (C 1 -C 6 ) alkylcarbonyloxy; a formyla
• the invention relates to the compounds of formula (I) in which: - W 1 represents an oxygen atom;
• p 1 or 2 and R 3 is hydrogen, a (C 1 -C 4 ) alkyl or the phenyl group;
• X ⁇ is an anion;
• - Ar ' is an unsubstituted phenyl group, a phenyl group substituted one or more times by a halogen, a nitro group, a hydroxyl group, a trifluoromethyl group, a (C 1 -C 4 ) alkyl group or a (C 1) group -C 4 ) alkoxy; or a pyridyl group;
• - Y represents a hydroxy group, an amino group, a (C 1 -C 7 ) alkyl-O- (CH 2 ) q - group; a group - (CH 2 ) q -NR 4 COR 14 ; a group R 15 COO- (CH 2 ) q -;
• R 4 represents hydrogen or a (C 1 -C 4 ) alkyl group
• R 14 represents a (C 1 -C 7 ) alkyl; phenyl; a pyrid-2-yl;
• R 15 represents a (C 1 -C 7 ) alkyl
• R 1 represents hydrogen or a (C 1 -C 4 ) alkyl group
• - R 2 represents a hydrogen; a (C 1 -C 4 ) alkyl; ⁇ - (C 1 -C 4 ) alkoxy- (C 2 - C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene; ⁇ -hydroxy- (C 2 -C 4 ) alkylene; ⁇ - (C 1 -C 4 ) alkyIthio- (C 2 -C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkoxycarbonyl- (C 2 -C 4 ) alkylene; ⁇ -carboxy- (C 2 -C 4 ) alkylene; a ⁇ - (C 1 -C 4 ) alkylcarbonyl- (C 2 -C 4 ) alkylene; a ⁇ -benzo
• - T represents the group -CH 2 - or one of the groups
• R 4 is hydrogen or a (C 1 -C 4 ) alkyl group, provided that T represents -CH 2 - when Q is oxygen and one of the groups
• - Z represents an unsubstituted phenyl, a phenyl substituted one or more times by a halogen, a hydroxy group, a nitro group, a (C 1 -C 4 ) alkyl group, a trifluoromethyl group, a (C 1 -C 4) group ) alkoxy; a naphthyl-1 group or a naphthyl-2 group;
• - Ar is an unsubstituted phenyl group or a phenyl group substituted one or more times by a substituent chosen from: a halogen atom, a trifluoromethyl, a hydroxy, a (C 1 -C 4 ) alkoxy, a (C 1 - C 4 ) alkyl, said substituents being identical or different; thienyl; benzothienyl; naphthyl; an indolyl optionally N-substituted by a (C 1 -C 4 ) alkyl or a benzyl;
• salts of the compounds of formula (I) can be formed.
• (I) such as picric acid or oxalic acid or an optically active acid, for example a mandelic or camphosulfonic acid, as those which form pharmaceutically acceptable salts, such as hydrochloride, hydrobromide, sulfate, l hydrogen sulfate, dihydrogen phosphate, methanesulfonate, methyl sulfate, maleate, fumarate, naphthalene-2 sulfonate, glycolate, gluconate, citrate, isethionate, benzenesulfonate, paratoluenesulfonate.
• pharmaceutically acceptable salts such as hydrochloride, hydrobromide, sulfate, l hydrogen sulfate, dihydrogen phosphate, methanesulfonate, methyl sulfate, maleate, fumarate, naphthalene-2 sulfonate, glycolate, gluconate, citrate, isethionate,
• the anions X ⁇ are those normally used to salify the quaternary ammonium ions, preferably the chloride, bromide, iodide, hydrogen sulfate, methanesulfonate, paratoluenesulfonate, acetate, benzenesulfonate ions.
• alkyl or alkoxy groups are straight or branched; halogen atom means a chlorine, bromine, fluorine or iodine atom.
• B represents a group B 5 or B 6
• aryl is meant a phenyl radical or a carbocyclic, bicyclic, ortho-condensed, C 9 -C 10 radical and in which at least one of the ring nuclei is aromatic
• heteroaryl is meant either a five or six-membered monocyclic aromatic heterocycle containing from one to four heteroatoms, said heteroatoms being chosen from oxygen, sulfur or nitrogen atoms, and said heterocycle being linked by a carbon atom of the carbon cycle or either an eight to ten-membered ortho-condensed bicyclic aromatic heterocycle containing from one to four heteroatoms as defined above.
• the radical Z represents a phenyl which is unsubstituted or substituted one or more times by a halogen atom, more particularly a chlorine, fluorine or iodine atom, a trifluoromethyl, a (C 1 -C 4 ) alkyl, hydroxy, (C 1 -C 4 ) alkoxy; naphthyl unsubstituted or substituted one or more times with a halogen, a trifluoromethyl, a (C 1 -C 4 ) alkyl, a hydroxy, a (C 1 -C 4 ) alkoxy; pyridyl; thienyl; indolyl; quinolyl; benzothienyl; an imidazolyl.
• a halogen atom more particularly a chlorine, fluorine or iodine atom, a trifluoromethyl, a (C 1 -C 4 ) alkyl, hydroxy, (C 1
• the substituent Ar is preferably a phenyl group advantageously substituted by two chlorine atoms or two fluorine atoms, more particularly in positions 3 and 4.
• R 1 and R 2 together constitute a group - (CH 2 ) n -CQ- in which n is equal to
• - Ar represents a 3,4-dichlorophenyl or a 3,4-difluorophenyl
• R 2 represents a methyl group
• - Ar represents a 3,4-dichlorophenyl or a 3,4-difluorophenyl
• R 2 represents a methyl group
• - W 1 represents a group -NR- in which R represents a methyl group
• - Ar represents a 3,4-dichlorophenyl or a 3,4-difluorophenyl
• R 1 and R 2 together constitute a group - (CH 2 ) n -CQ- in which n is equal to 2 and Q is H 2 or oxygen:
• - Ar represents an unsubstituted phenyl or phenyl substituted one or more times with a substituent selected from a halogen atom, trifluoromethyl, hydroxy, alkoxy, C 1 -C 4 alkyl, C 1 - C 4 , said substituents being identical or different; thienyl; benzothienyl; naphthyl; indolyl optionally N-substituted by C 1 -C 4 alkyl or benzyl;
• - Z represents an unsubstituted phenyl, a phenyl substituted one or more times by a halogen, a hydroxy group, a nitro group, a (C 1 -C 4 ) alkyl group, a trifluoromethyl group, a (C 1 -C 4) group ) alkoxy; a naphthyl-1 group or a naphthyl-2 group;
• T and A are as defined above for (I);
• p 1 or 2 and R 3 is hydrogen, a (C 1 -C 4 ) alkyl or the phenyl group;
• X ⁇ is an anion;
• - Ar ' is an unsubstituted phenyl group, a phenyl group substituted one or more times by a halogen, a nitro group, a hydroxyl group, a trifluoromethyl group, a (C 1 -C 4 ) alkyl group or a (C 1) group -C 4 ) alkoxy; or a pyridyl group;
• - Y represents a hydroxy group, an amino group, a (C 1 -C 7 ) alkyl-O- (CH 2 ) q - group; a group - (CH 2 ) q -NR 4 COR 14 ; a group R 15 COO- (CH 2 ) q -;
• R 2 represents a methyl group
• - Ar represents an unsubstituted phenyl or phenyl substituted one or more times with a substituent selected from a halogen atom, trifluoromethyl, hydroxy, alkoxy, C 1 -C 4 alkyl, C 1 - C 4 , said substituents being identical or different; thienyl; benzothienyl; naphthyl; indolyl optionally N-substituted by C 1 -C 4 alkyl or benzyl;
• - Z represents an unsubstituted phenyl, a phenyl substituted one or more times by a halogen, a hydroxy group, a nitro group, a (C 1 -C 4 ) alkyl group, a trifluoromethyl group, a (C 1 -C 4) group ) alkoxy; a naphthyl-1 group or a naphthyl-2 group;
• p 1 or 2 and R 3 is hydrogen, a (C 1 -C 4 ) alkyl or the phenyl group;
• X ⁇ is an anion;
• - Ar ' is an unsubstituted phenyl group, a phenyl group substituted one or more times by a halogen, a nitro group, a hydroxyl group, a trifluoromethyl group, a (C 1 -C 4 ) alkyl group or a (C 1) group -C 4 ) alkoxy; or a pyridyl group;
• - Y represents a hydroxy group, an amino group, a (C 1 -C 7 ) alkyl-O- (CH 2 ) q - group; a group - (CH 2 ) q -NR 4 COR 14 ; a group R 15 COO- (CH 2 ) q -;
• the present invention relates to obtaining the compounds of formula (I) and their salts.
• process A is suitable for obtaining the compounds of formula (I) in which both R 1 and R 2 together constitute a group - (CH 2 ) n -CQ wherein Q is oxygen and W 1 represents an oxygen atom.
• This process consists of:
• Hal represents a halogen atom, preferably bromine
• a and Z are as defined above for a compound of formula (I)
• T is -CH 2 -
• a base such as for example sodium hydride or potassium tert-butoxide
• G represents a methyl, phenyl, tolyl, trifluoromethyl group
• step 3 The substitution carried out in step 3) is carried out at room temperature with the derivative Hal- (CH 2 ) m - O - E 2 in solution in an organic solvent, such as dimethylformamide, tetrahydrofuran and in the presence of a hydride, such as for example sodium hydride.
• an organic solvent such as dimethylformamide, tetrahydrofuran
• a hydride such as for example sodium hydride.
• Step 6) of process A consists in reacting the compound of formula (IX) with an amine of formula (X a ), (X b ), (Xc), (Xd), (Xe), (Xf), (Xg) or (Xh). It is generally carried out in solution in an organic solvent, such as for example dimethylformamide at a temperature of between 20 ° and 80 ° C. approximately.
• the compounds (I) obtained are isolated and purified according to the usual methods, such as for example chromatography or recrystallization.
• This process consists of:
• R ′ 2 represents a hydrogen, a (C 1 -C 7 ) alkyl, a ⁇ - (C 1 -C 4 ) alkoxy- ( C 2 -C 4 ) alkylene, ⁇ -hydroxy- (C 2 -C 4 ) alkylene, ⁇ - (C 1 -C 4 ) alkylthio- (C 2 -C 4 ) alkylene, ⁇ - (C 1 - C 4 ) alkoxycarbonyl- (C 2 -C 4 ) alkylene, a ⁇ -carboxy- (C 2 -C 4 ) alkylene, a ⁇ - (C 1 -C 4 ) alkylcarbonyl- (C 2 -C 4 ) alkylene, a ⁇ -R 6 R 7 NCO- (C 2 -C 4 ) alkylene, a ⁇ -cyano- (C 1 -C 3 ) alkylene, a ⁇ -cyano- (C 1 -C 3
• R ′ 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, protect the amino function as indicated in step 2) then protect the hydroxyl or , optionally transform the group R ' 2 into R " 2 to obtain a compound of formula:
• R " 2 represents a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene, a ⁇ -benzoyloxy- (C 2 -C 4 ) alkylene, a ⁇ -benzyloxy- (C 2 -C 4 ) alkylene, a ⁇ -formyloxy- (C 2 -C 4 ) alkylene, a ⁇ -R 5 NHCOO- (C 2 -C 4 ) alkylene, a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene, a ⁇ -R 10 CON R 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 12 OCONR 11 - (C 2 -C 4 ) alkylene , a ⁇ -R 6 R 7 NCON R 11 - (C 2 -C 4 ) alkylene,
• step 2) treating the compound (XIII) or (XIIIbis) obtained in step 2) or in step 3), it being understood that when R ′ 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, l hydroxyl is protected, or when R " 2 represents a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene group in which R 8 represents a hydrogen, the amine is protected, with a compound of formula (VI ): Hal- (CH 2 ) m -OE 2 in which E 2 is an O-protecting group, such as the tetrahydropyran-2-yl group, to form the compound of formula:
• B ' represents a group B 2 , B 3 , B 4 , B 5 , B 6 , B 7 or B 8 as defined above for a compound of formula (I); 1 8) deprotecting the N-protecting group of the compound (XVIII) by treatment in a strong acid medium, for example HCl, to obtain the compound of formula:
• Hal represents a halogen atom, preferably bromine
• a and Z are as defined above, when R 1 and R 2 are distinct and when a compound of formula (I) must be prepared where T is -CH 2 -;
• R ' 4 is a (C 1 -C 4 ) alkyl group, when it is necessary to prepare a compound of formula (I) where T is -CO-NR 4 - in which R 4 is a (C 1 -C 4 ) alkyl;
• step 10 and, after possible deprotection of the hydroxyl or amino groups, or possible transformation of Y "into Y ', optionally transforming the product obtained in step 9) into one of its salts with a mineral or organic acid.
• step 4 ' Either, when a cyclic tertiary amine of formula (Xb) has been used and after deprotection of the hydroxyl or amino groups, the product thus obtained is isolated in step 4 ') or optionally exchanging the sulfonate anion of the quaternary salt thus obtained with another pharmaceutically acceptable anion.
• process C and on the condition that T is different from -CO-NH- or that -TA- is different from -CO- (CH 2 ) t -,
• R ' 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, the hydroxyl is protected, or optionally the group R' 2 is transformed into R" 2 to obtain a compound of formula: )
• R " 2 represents a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene, a ⁇ -benzoyloxy - (C 2 -C 4 ) alkylene, a ⁇ -benzyloxy- (C 2 -C 4 ) alkylene, a ⁇ -formyloxy- (C 2 -C 4 ) alkylene, a ⁇ -R 5 NHCOO- (C 2 -C 4 ) alkylene, a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene, a ⁇ -R 10 CONR 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 12 OCONR 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 6 R 7 NCONR 11 - (C 2 -C 4 )
• step 8 - either, when a cyclic secondary amine of formula (Xa), (Xc), (Xd), (Xe), (Xf), (Xg) or (Xh) is used and after possible deprotection of the hydroxyl groups or amines, or possible transformation of Y "into Y ', the product obtained in step 7") is optionally transformed into one of its salts with a mineral or organic acid;
• step 7 Either, when using a cyclic tertiary amine of formula (Xb), and after possible deprotection of the hydroxyl or amine group, the product thus obtained is isolated in step 7 ”) or alternatively the sulfonate anion is exchanged for quaternary salt thus obtained with a pharmaceutically acceptable anion.
• step 9) of process B or in step 2 ') of process C or in step 1 ") of process C as the acid derivative (IIIa), the acid itself is used.
• the acid derivative (IIIa) is used.
• the reaction is carried out in a solvent such as dichloromethane, at a temperature between 0oC and room temperature and in the presence of a base such as triethylamine.
• a base such as triethylamine.
• an isocyanate of formula (IIIc) is used, the reaction is carried out in an inert solvent such as dichloromethane or benzene overnight at room temperature.
• the reaction is carried out in a solvent such as toluene or 1,2-dichloroethane, at a temperature between 0oC and 110oC and in the presence of a base, such as triethylamine.
• a solvent such as toluene or 1,2-dichloroethane
• Steps 3) of process B or 4 ") of process C 'in which the compound (VI) is reacted are carried out as described previously in process A.
• step 3) of process B or in step 2 ") of process C ' optionally the compound thus obtained is subjected to a subsequent treatment to prepare a compound of formula (XIV) or a compound of formula (XXIII bis ) by transformation of the RS group into R " 2 or optionally when R ' 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, the hydroxyl is protected.
• R ' 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene
• optionally an O-acylation reaction is carried out according to methods known to those skilled in the art, to obtain a compound of formula (XIV) or a compound of formula (XXIII bis) in which R " 2 represents a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene or a ⁇ -benzoyloxy- (C 2 -C 4 ) alkylene.
• R ' 2 represents a ⁇ -cyano- (C 1 -C 3 ) alkylene by reduction of the nitrile group according to methods known to those skilled in the art.
• a compound of formula (XIV) or a compound of formula (XXIII bis) in which R " 2 represents a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene can be prepared by following the various steps of the process described in SCHEME 1.
• process D is suitable for preparing compounds of formula (I) in which both R 1 and R 2 together constitute a group - (CH 2 ) n -CQ- in which O is oxygen and W 1 represents a group -NR- as defined for (I).
• This process consists of:
• Hal represents a halogen atom, preferably bromine
• a and Z are as defined above for a compound of formula (I)
• T is -CH 2 -
• a base such as sodium hydride or potassium tert-butoxide
• G represents a methyl, phenyl, tolyl or trifluoromethyl group
• This process consists of:
• R ′ 2 represents a hydrogen, a (C 1 -C 7 ) alkyl, a ⁇ - (C 1 -C 4 ) alkoxy- (C 2 -C 4 ) alkylene, a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, a ⁇ - (C 1 -C 4 ) alkylthio- (C 2 -C 4 ) alkylene, a ⁇ - (C 1 -C 4 ) alkoxycarbonyl- (C 2 -C 4 ) alkylene, a ⁇ -carboxy- (C 2 -C 4 ) alkylene, a ⁇ - (C 1 -C 4 ) alkylcarbonyl- (C 2 -C 4 ) alkylene, a ⁇ -R 6 R 7 NCO- (C 2 -C 4 ) alkylene, a ⁇ -cyano-
• Hal represents a halogen atom, preferably bromine
• a and Z are as defined above for (I), when R 1 and R 2 are distinct and when a compound of formula (I) must be prepared where T is -CH 2 -;
• R ' 4 is a (C 1 -C 4 ) alkyl group, when it is necessary to prepare a compound of formula (I) where T is -CO-NR 4 - in which R 4 is a (C 1 -C 4 ) alkyl;
• R ' 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, protect the hydroxyl, or optionally, transform the group R' 2 into R " 2 to obtain a compound of formula:
• R " 2 represents a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene, a ⁇ -benzoyloxy- (C 2 -C 4 ) alkylene, a benzyloxy- (C 2 -C 4 ) alkylene, a ⁇ -formyloxy- (C 2 -C 4 ) alkylene, a ⁇ -R 5 NHCOO- (C 2 -C 4 ) alkylene, a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene, a ⁇ -R 10 CONR 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 12 OCONR 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 6 R 7 NCONR 11 - (C 2 -C 4 )
• R' 2 represents a ⁇ -hydroxy- (C 2 -C 4 ) alkylene, the amino function is protected as indicated in step 2 ') then it is protected hydroxyl or, optionally, the group R ′ 2 is transformed into R ′′ 2 to obtain a compound of formula:
• R " 2 represents a ⁇ - (C 1 -C 4 ) alkylcarbonyloxy- (C 2 -C 4 ) alkylene, a ⁇ -benzoyloxy- ( C 2 -C 4 ) alkylene, ⁇ -benzyloxy- (C 2 -C 4 ) alkylene, ⁇ -formyloxy- (C 2 -C 4 ) alkylene, ⁇ -R 5 NHCOO- (C 2 -C 4 ) alkylene, a ⁇ -R 8 R 9 N- (C 2 -C 4 ) alkylene, a ⁇ -R 10 CON R 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 12 OCONR 11 - (C 2 - C 4 ) alkylene, a ⁇ -R 6 R 7 NCON R 11 - (C 2 -C 4 ) alkylene, a ⁇ -R 10 CON R 11 - (C 2 -C 4 ) alkylene
• B ' represents a group B 2 , B 3 , B 4 , B 5 , B 6 , B 7 or B 8 as defined above for a compound of formula (I);
• Hal represents a halogen atom, preferably bromine
• a and Z are as defined above, when R 1 and R 2 are distinct and when a compound of formula (I) must be prepared where T is -CH 2 -;
• R ′ 4 is a (C 1 -C 4 ) alkyl group, when it is necessary to prepare a compound of formula (1) where T is -CO-NR 4 - in which R 4 is a (C 1 -C 4 ) alkyl;
• step 7 ' the product obtained in step 7 ') is optionally transformed into one of its salts with a mineral or organic acid .
• step 2) of process D or step 3) or 4) of process E or in steps l ') or 3') of the variant of process E the protective group E 3 is removed.
• E 3 represents a tetrahydropyran-2-yl group
• deprotection is carried out by acid hydrolysis using hydrochloric acid in a solvent such as ether, methanol or a mixture of these solvents, or using p- toluenesulfonate in a solvent such as methanol, or alternatively using an Amberlyst ® resin in a solvent such as methanol.
• step 3) of process D or in step 5) of process E or in step 4 ') of the variant of process E the reaction of a sulfonyl chloride of formula (XXIX) is carried out in the presence of a base such as triethylamine, in an inert solvent such as dichloromethane, benzene or toluene and at a temperature between -20oC and room temperature.
• a base such as triethylamine
• an inert solvent such as dichloromethane, benzene or toluene
• step 1) of process E or in step 7 ') of the variant of process E the reaction with a compound (III), (Illa), (Illb), (IIIc) or (Illd) s' performs as described previously in method A, B or C.
• step 2) of method E or in step 3 ') of the variant of method E the transformation of the substituent R' 2 into R " 2 is carried out as described previously in method B or C.
• step 4) of process D) or in step 6) of process E or in step 5 ') of the variant of process E the reaction with a compound of formula (Xa), (Xb), (Xc), (Xd), (Xe), (Xf), (Xg) or (Xh) is carried out in an inert solvent such as N, N-dimethylformamide or acetonitrile, at a temperature between 20oC and 90oC and with or without a base.
• a base is chosen from organic bases such as triethylamine,
• N, N-diisopropylethylamine or N-methylmorpholine or among the carbonates or bicarbonates of alkali metal such as potassium carbonate, sodium carbonate or sodium bicarbonate.
• This protection can be carried out using conventional protective groups, such as those described in Protective Groups in Organic Chemistry, JFW McOmie, Ed. Plénum Press, 1973 and in Protective Groups in
• O-protective groups optionally used to obtain a compound of formula (I) in which R 2 represents a ⁇ -hydroxy (C 2 -C 4 ) alkylene and / or Y 'represents a hydroxy are the well-known conventional O-protective groups skilled in the art such as for example tetrahydropyran-2-yl, acetyl or benzoyl.
• N-protective groups optionally used to obtain a compound of formula (I) in which Y ′ represents an amino are the conventional N-protective groups well known to those skilled in the art such as for example the trityl group, methoxytrityl, tert-butoxycarbonyl or benzyloxycarbonyl.
• the compound of formula (I) obtained represents the final product in which R 2 represents an ⁇ -acetoxy (C 2 -C 4 ) alkylene and / or Y 'represents an acetoxy or R 2 represents a ⁇ -benzoyloxy (C 2 -C 4 ) alkylene.
• B represents B 2 , B 3 , B 4 , B 5 , B 6 , B 7 or B 8 ,
• B 7 or B 8 is obtained in the form of a free base, the salification is carried out by treatment with the chosen acid in an organic solvent.
• the free base dissolved for example in an alcohol such as isopropanol, or in an ether such as diethyl ether, with a solution of the chosen acid in the same solvent, the corresponding salt which is isolated according to conventional techniques.
• the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, dihydrogen phosphate, methanesulfonate, oxalate, maleate, fumarate, 2-naphthalene sulfonate, benzenesulfonate are prepared.
• B 3 , B 4 , B 5 , B 6 , B 7 or B 8 can be isolated in the form of one of their salts, for example the hydrochloride or the oxalate; in this case, if necessary, the free base can be prepared by neutralizing said salt with an inorganic or organic base, such as sodium hydroxide or triethylamine or with an alkali carbonate or bicarbonate, such as carbonate or sodium or potassium bicarbonate.
• an inorganic or organic base such as sodium hydroxide or triethylamine or with an alkali carbonate or bicarbonate, such as carbonate or sodium or potassium bicarbonate.
• the GSO3 sulfonate anion resulting from the reaction between the tertiary amine of formula (Xb) and the compound of formula (IX), (XXII), (XXVII), (XXXIII) or (XXXIX), can be exchanged, in situ or after isolation of the compound of formula (I) in which B represents a group B 1 in which X ⁇ is the GSO 3 ⁇ ion, by another anion X ⁇ , according to conventional methods, for example by exchange in solution with a saturated solution of sodium chloride or with a hydrochloric acid solution when X represents a chloride anion, or by exchange of the anion by elution of the compound (I) on an ion exchange resin, for example Amberlite IRA 68 ® or Duolite A 375 ® .
• an ion exchange resin for example Amberlite IRA 68 ® or Duolite A 375 ® .
• the O-protected compound 3 is then substituted by the group - (CH 2 ) n -COOEt by reaction with an ethyl bromoalkylcarboxylate in which the alkyl is C 1 -C 3 after having been treated with lithium diisopropylamide ( LDA).
• LDA lithium diisopropylamide
• a reducing agent such as for example aluminum and lithium hydride
• Compound 8 is then N-deprotected and compound 9 thus obtained is O-protected to give a compound of formula (XI) expected.
• the reduction of the nitriles of formula (XXVIII) is carried out by hydrogenation in an alkanol, such as ethanol, in the presence of a catalyst, such as for example nickel.
• nitriles of formula (XXVIII) are prepared from the nitriles of formula 3 of
• DIAGRAM 2 above by possible alkylation according to conventional methods and well known to those skilled in the art.
• an ⁇ -aminonitrile compound 10 is carried out from an aldehyde 1 according to the method described in Tetrahedron Letters, 1984, 25 (41), 4583-4586 and using an amine of formula HO- (CH 2 ) n -NHR in which m and R are as defined for (I).
• the hydroxy group of compound 10 is then protected by reaction, for example, with 3,4-dihydro-2H-pyrane.
• the compound 11 thus obtained is then substituted with the group - (CH 2 ) n -COOEt by reaction with an ethyl bromoalkylcarboxylate in which the alkyl is C 1 -C 3 after being treated with lithium diisopropylamide (LDA).
• LDA lithium diisopropylamide
• the resulting compound 12 is subjected to hydrogenation in the presence of Raney ® nickel to obtain the compound of formula (XXX) expected.
• a reducing agent such as, for example, aluminum and lithium hydride
• solvent such as diethyl ether, toluene or tetrahydrofuran
• N-protecting group E4 such as tert-butoxycarbonyl (Boc) according to the methods known to those skilled in the art.
• the compound 14 thus obtained is treated with a strong base such as lithium diisopropylamide (LDA) to form a carbanion which is reacted with a compound of formula Br- (CH 2 ) n -CO 2 And in which n is such as defined for (I), to obtain compound 15.
• a strong base such as lithium diisopropylamide (LDA)
• LDA lithium diisopropylamide
• n 2
• the carbonyl groups of compound 18 are reduced by the action of a reducing agent such as aluminum and lithium hydride to obtain the expected compound of formula (XXXrV).
• a reducing agent such as aluminum and lithium hydride
• Reducing the nitrile 19 is carried out either by the action of a reducing agent such as aluminum and lithium hydride according to conventional methods, either by hydrogenation in the presence of a catalyst such as Raney nickel ® e.g. .
• a catalyst such as Raney nickel ® e.g. .
• substitution of the primary amine is carried out to introduce the substituent R ′ 2 different from hydrogen according to the methods previously described for a compound of formula (XI).
• the piperidines of formula (Xa) are known or prepared by known methods, such as those described in EP-A-0428434, EP-A-0474561, EP-A-0512901 and EP-A-0515240.
• piperidines of formula (Xa) can also be prepared by methods well known to those skilled in the art, such as those described in the following publications; J. Heterocyclic. Chem., 1986, 23, 73-75
• the compounds of formula (Xa) are generally prepared in protected form on the nitrogen of piperidine; after a deprotection step, the compounds of formula (Xa) are obtained themselves.
• the compounds of formula (Xa) in which Y "represents a hydroxyl and which carry a protective group on the nitrogen of piperidine, can undergo a Ritter reaction by action of acetonitrile to prepare the compounds of formula (Xa) in which Y "is an acetamido.
• a Ritter reaction by action of acetonitrile to prepare the compounds of formula (Xa) in which Y "is an acetamido.
• the compounds of formula (Xa) in which Y "is an amino are then prepared.
• R 22 H.
• a compound of formula (Xa) is prepared in which Y "represents a group -NR 16 R 17 in which R 16 and R 17 together with the nitrogen atom to which they are bonded constitute a heterocycle, by application or adaptation of the Bruylants reaction (Bull. Soc. Chim. Belges, 1924, 33, 467 and Tetrahedron Letters, 1988, 29 (52), 6827-6830).
• a compound of formula (Xa) is prepared in which Y "represents a group
• R 18 and R 19 each represent a hydrogen, from a compound of formula (Xa) in which Y "represents a group -CH 2 -CH 2 -OH, by application or adaptation of the method described in J. Med. Chem., 1989, 32, 391-396.
• -NR 16 R 17 in which R 16 represents a hydrogen and R 17 represents a (C 1 - C 7 ) alkyl, or respectively a (C 3 -C 7 ) cycloalkylmethyl or a benzyl can be carried out a reduction of a compound of formula (Xa) in which Y "represents a group - (CH 2 ) q -NR 4 COR 14 in which q is zero, R 4 represents hydrogen and R 14 represents hydrogen or a (C 1 -C 6 ) alkyl, or respectively (C 3 -C 7 ) cycloalkyl or phenyl.
• the reaction is carried out by means of a reducing agent such as lithium aluminum hydride in a solvent such as tetrahydrofuran at the reflux temperature of the solvent.
• the compounds of formula (Xa) can be prepared in which Y "represents a group -NR 16 R 17 in which R 16 represents a (C 1 -C 4 ) alkyl and R 17 represents a (C 1 -C 7 ) alkyl, or respectively a (CC 7 ) cycloalkylmethyl or a benzyl starting from a compound of formula (Xa) in which Y "represents a group - (CH 2 ) q -NR 4 COR 14 in which q is zero, R 4 represents a (C 1 -C 4 ) alkyl and R 14 represents a hydrogen or a (C 1 -C 6 ) alkyl, or respectively a (C 3 -C 7 ) cycloalkyl or a phenyl.
• the compounds of formula (Xa) in which Y "represents a group -NR 16 R 17 in which R 16 represents a (C 5 -C 7 ) alkyl can be
• a compound of formula (Xa) is prepared in which Y "represents a group - (CH 2 ) q -NR 4 COR 14 in which R 4 and R 14 together represent a group - (CH 2 ) 3 - or - (CH 2 ) 4 - by application or adaptation of the method described in J. Med. Chem., 1985, 28, 46-50.
• a compound of formula (Xa) in which Y "represents a group - (CH 2 ) q -OH in which q is one or respectively two is prepared, by reduction of a compound of formula (Xa) in which Y" represents a methoxycarbonyl or respectively a methoxycarbonylmethyl according to the method described in Chem. Ber., 1975, 108, 3475-3482.
• an acid chloride R 15 COCI on the compounds of formula (Xa) in which Y "represents a group - (CH 2 ) q -OH, the compounds of formula are obtained
• a compound of formula (Xa) in which Y "represents a carboxy can be prepared by hydrolysis of a compound of formula (Xa) in which Y" represents a cyano according to methods known to those skilled in the art.
• a compound of formula (Xa) in which Y "represents a carboxymethyl can be prepared according to the method described in Chem. Ber., 1975, 108, 3475-3482.
• a compound of formula (Xa) in which Y "represents a (C 1 -C 7 ) alkoxycarbonyl or respectively a (C 1 -C 7 ) alkoxycarbonylmethyl can be prepared from a compound of formula (Xa) in which Y" represents a carboxy or a carboxymethyl respectively, by esterification reaction according to methods well known to those skilled in the art.
• x is one and Y "represents a (C 1 -C 7 ) alkoxycarbonyl, a 4- (C 1 -C 7 ) alkoxycarbonylpiperidine is reacted with a benzyl halide optionally substituted in the presence of a base such as sodium hydride, potassium tert-butoxide or sodium diisopropylamide in a solvent such as tetrahydrofuran, N, N-dimethylformamide or dimethyl sulfoxide, at a temperature between -78 ° C and room temperature. deprotection, the compound of formula (Xa) is obtained.
• a base such as sodium hydride, potassium tert-butoxide or sodium diisopropylamide
• a solvent such as tetrahydrofuran, N, N-dimethylformamide or dimethyl sulfoxide
• the piperazines of formula (Xc) are known or prepared by known methods such as those described in EP-A-0474561.
• the piperidines of formula (Xd) are known or prepared by known methods, such as those described in WO 94/10146.
• the piperidines of formula (Xf) are known or prepared by known methods, such as those described in EP-A-0630887.
• the piperidines of formula (Xg) are known or prepared by known methods, such as those described in WO 94/26735.
• V 1 represents hydrogen; an O-protecting group, in particular the tetrahydropyran-2-yl group; a G-SO 2 group in which G represents a methyl, phenyl, tolyl or trifluoromethyl group;
• V 2 represents hydrogen; an N-protecting group such as tert-butoxycarbonyl; a TAZ group in which, T, A and Z are as defined for (I).
• Wi represents a group -NR-
• the diastereoisomers are then separated by conventional methods such as crystallization or chromatography and then by hydrolysis, the optically pure enantiomers are obtained.
• the compounds of formula (I) above also include those in which one or more hydrogen or carbon atoms have been replaced by their radioactive isotope, for example tritium, carbon-14 or iodine-125.
• radioactive isotope for example tritium, carbon-14 or iodine-125.
• the tests were carried out according to X. Emonds-Alt et al. (Eur. J. Pharmacol., 1993, 250, 403-413).
• the compounds according to the invention have an affinity for the tachykinin receptors mentioned above, with an inhibition constant Ki of less than 10 - 8 M.
• the compounds of the present invention are in particular active principles of pharmaceutical compositions, the toxicity of which is compatible with their use as medicaments.
• the compounds of the present invention are generally administered in dosage units.
• Said dosage units are preferably formulated in pharmaceutical compositions in which the active principle is mixed with a pharmaceutical excipient.
• the present invention relates to pharmaceutical compositions containing, as active principle, a compound of formula (I) or one of its pharmaceutically acceptable salts.
• compositions according to the invention advantageously contain from 0.5 to 1000 mg of active principle, preferably from 2.5 to 250 mg of active principle.
• the compounds of formula (I) above and their pharmaceutically acceptable salts can be used in daily doses of 0.01. 100 mg per kg of body weight of the mammal to be treated, preferably in daily doses of 0.1 to 50 mg / kg.
• the dose may preferably vary from 0.5 to 4000 mg per day, more particularly from 2.5 to 1000 mg depending on the age of the subject to be treated or the type of treatment: prophylactic or curative.
• compositions of the present invention for oral, sublingual, inhaled, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active ingredients which can be administered in unit administration forms, in admixture with conventional pharmaceutical carriers, animals and humans.
• suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, implants, forms subcutaneous, intramuscular, intravenous, intranasal or intraocular administration and forms of rectal administration.
• the main active principle is mixed with a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or analogues.
• a pharmaceutical vehicle such as silica, gelatin, starch, lactose, magnesium stearate, talc, gum arabic or analogues.
• the tablets can be coated with sucrose, various polymers or other suitable materials or they can be treated so that they have an activity. prolonged or delayed and that they continuously release a predetermined amount of active ingredient.
• a preparation in capsules is obtained by mixing the active principle with a diluent such as a glycol or an ester of glyccrol and by incorporating the mixture obtained in soft or hard capsules.
• a diluent such as a glycol or an ester of glyccrol
• a preparation in the form of a syrup or elixir may contain the active principle together with a sweetener, preferably calorie-free, methylparaben and propylparaben as an antiseptic, as well as a flavoring agent and an appropriate color.
• a sweetener preferably calorie-free, methylparaben and propylparaben as an antiseptic, as well as a flavoring agent and an appropriate color.
• the water-dispersible powders or granules may contain the active principle in admixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners or taste.
• Suppositories are used for rectal administration which are prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
• aqueous suspensions, isotonic saline solutions or sterile and injectable solutions which contain pharmacologically compatible dispersing agents and / or wetting agents, for example propylene glycol or butylene glycol.
• an aerosol containing, for example, sorbitan trioleate or oleic acid, as well as trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane or any other biologically compatible propellant is used; one can also use a system containing the active principle, alone or associated with an excipient, in powder form.
• the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives.
• compositions can also contain other active products such as, for example, bronchodilators, antitussives or antihistamines.
• the present invention relates to the use of the products of formula (I) for the preparation of medicaments intended to treat physiological disorders associated with an excess of tachykinins and all the neurokinin-dependent pathologies of the respiratory system, gastro -intestinal, urinary, immune, cardiovascular and central nervous system as well as pain and migraine.
• the products of formula (I) for the preparation of medicaments intended to treat physiological disorders associated with an excess of tachykinins and all the neurokinin-dependent pathologies of the respiratory system, gastro -intestinal, urinary, immune, cardiovascular and central nervous system as well as pain and migraine.
• inflammations such as chronic obstructive respiratory diseases, asthma, allergies, rhinitis, coughs, bronchitis, hypersensitivity for example to pollens and dust mites, arthritis, rheumatoid, osteoarthritis, psoriasis, ulcerative colitis, Crohn's disease, inflammation of the intestines (irritable colon), prostatitis, neurological bladder, cystitis, urethritis, nephritis,
• rheumatoid arthritis for example rheumatoid arthritis, psoriasis, Crohn's disease, diabetes, lupus,
• neurodegenerative diseases of the central nervous system of the neuropsychiatric or neurological type such as anxiety, depression, psychosis, schizophrenia, mania, dementia, epilepsy, Parkinson's disease, Alzheimer's disease, drugs -dependence, Down syndrome and Huntington's chorea as well as neurodegenerative diseases,
• - diseases of the cardiovascular system such as hypertension, vascular aspects of migraine, edema, thrombosis, angina pectoris, vascular spasms.
• the present invention also includes a method for treating said conditions at the doses indicated above.
• NaCl sodium chloride
• MgSO 4 magnesium sulfate
• hydrochloric ether saturated solution of hydrochloric acid in ether
• silica H silica gel 60H, sold by Merck (DARMSTAD)
• a solution of 12.6 g of the compound obtained in the preceding step in 160 ml of ether is cooled to -70 ° C., 32 ml of a 1.5 M solution of lithium diisopropylamide in hexane is added and the mixture is left for 15 minutes. with stirring at -70oC Then add a solution of 8.8 g of ethyl 3-bromopropionate in ether, allow the temperature to rise to 0oC and stir for 3 hours.
• the reaction mixture is poured onto a saturated NH 4 CI solution, the organic phase is decanted, washed with water, dried over MgSO 4 and evaporated under vacuum. 15 g of the expected product are obtained, which product is used as it is in the next step.
• step b) To a solution of 31.9 g of the compound obtained in Preparation 1, step b) in 400 ml of absolute EtOH, 100 ml of concentrated ammonia is added and Raney ® nickel. Hydrogenation is carried out at AT and at atmospheric pressure. After absorption of the theoretical volume of hydrogen, the catalyst was filtered through Celite ® and the filtrate concentrated in vacuo. The residue is taken up in ether, washed with water, with a saturated NaCl solution, dried over MgSO 4 and concentrated in vacuo. 30.6 g of oil of the expected product are obtained, which product is used as it is in the next step.
• Hydrogenation is carried out at RT and at atmospheric pressure a mixture of 10 g of the compound obtained in the preceding step, 1 g of 10% palladium on carbon, in 200 ml of MeOH.
• the catalyst is filtered and the filtrate is evaporated under vacuum.
• the residue is taken up in ether and the precipitate formed is drained.
• reaction mixture is then poured onto a mixture of ice / buffer solution pH 2, extracted with ether, washed with water and then with a 10% solution of Na 2 CO 3 , the organic phase is dried over MgSO 4 and concentrated in vacuo.
• the residue is purified by chromatography on silica gel, eluting successively with heptane, a heptane / AcoEt gradient and then with pure ethyl acetate to give 0.9 g of the expected product which is used as it is in the next step.
• This compound can also be obtained by following the two steps of the process described below.
• a mixture of 1 g of the compound obtained in the preceding step (in the form of free base) and 0.15 g of 5% palladium on carbon in 80 ml of acetic acid is hydrogenated at RT and at atmospheric pressure.
• the catalyst is filtered through Celite® and the filtrate is concentrated under vacuum.
• the residue is taken up in a 5N NaOH solution, extracted with DCM, the organic phase is washed with a 5N NaOH solution, dried over MgSO 4 and the thirst is evaporated empty the filtrate.
• step b) To a solution of 8 g of 4-acetamido-4-phenylpiperidine hydrochloride in 6 ml of water, 5 ml of concentrated NaOH is added, extracted three times with DCM and dried over MgSO 4 . 4.7 g of the compound obtained in EXAMPLE 9, step b) are added to this solution and concentrated in vacuo. 10 ml of DMF are added to the residue obtained and the mixture is heated at 70 ° C. for 2 hours. The reaction mixture is poured onto ice water, extracted with AcOEt, washed with a 1N NaOH solution, with water, with saturated NaCl solution, dried over MgSO 4 and concentrated in vacuo. 6.0 g of the expected product are obtained, which product is used as it is in the next step.
• step b) 0.127 g of phenylacetic acid in 10 ml of DCM, 0.46 ml of triethylamine is added, then 0.5 g of BOP.
• the mixture is concentrated under vacuum, the residue is taken up in AcOEt, washed with water, with a 1N NaOH solution, with a saturated NaCl solution, dried over MgSO 4 and concentrated under vacuum.
• the residue is chromatographed on silica gel H, eluting with DCM, then with a DCM / MeOH mixture (94/6; v / v).
• the product obtained is taken up in
• step A of EXAMPLE 15 To a solution of 4 g of the compound obtained in step A of EXAMPLE 15 in 20 ml of water, 1 g of NaOH in pellets is added, then 40 ml of dioxane and 2.8 g of ditert-butyldicarbonate and leaves stirring for two hours at RT.
• the dioxane is concentrated under vacuum, the aqueous phase is extracted with ether, the organic phase is washed with water, dried over MgSO 4 and the solvent is evaporated under vacuum.
• the residue is chromatographed on silica, eluting with heptane and then with the gradient of the heptane / AcOEt mixture up to (20/80; v / v). 2.5 g of the expected product are obtained, which product is used as it is.
• a mixture of 2.6 g of the compound obtained in the preceding step, 5 g of 4-acetamido-4-phenylpiperidine p-toluenesulfonate, 4.4 g of potassium carbonate in 50 ml of the mixture is heated at 80 ° C. for two hours. 'acetonitrile.
• the reaction mixture is concentrated under vacuum, the residue is extracted with AcOEt, the organic phase is washed with water, with a 1N NaOH solution, with a saturated NaCl solution, dried over MgSO 4 and the solvent is evaporated under vacuum.
• the residue is chromatographed on silica H, eluting with DCM, then with a DCM / MeOH mixture (90/10; v / v). 3.1 g of the expected product are obtained, which product is used as it is.
• the reaction mixture is concentrated under vacuum, the residue is extracted with AcOEt, the organic phase is washed with water and with 1N NaOH solution, dried over MgSO 4 and the solvent is evaporated under vacuum.
• the residue is chromatographed on silica H, eluting with DCM and then with the gradient of the DCM / MeOH mixture until (90/10; v / v).

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9461551

Family Applications (1)

Country Status (7)

Families Citing this family (41)

Family Cites Families (4)

• 1994
  • 1994-03-29 FR FR9403701A patent/FR2718136B1/fr not_active Expired - Fee Related
• 1995
  • 1995-03-29 AU AU21432/95A patent/AU2143295A/en not_active Abandoned
  • 1995-03-29 US US08/549,664 patent/US5726313A/en not_active Expired - Fee Related
  • 1995-03-29 HU HU9503402A patent/HUT76137A/hu unknown
  • 1995-03-29 EP EP95914435A patent/EP0700386A1/de not_active Withdrawn
  • 1995-03-29 JP JP7525010A patent/JPH08511278A/ja active Pending
  • 1995-03-29 WO PCT/FR1995/000391 patent/WO1995026338A1/fr not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events